Latest News

Alpha-1 Symposium at American Thoracic Society International Conference

The landmark discovery of alpha-1 antitrypsin deficiency was 50 years ago in 1963, and to mark this the American Thoracic Society (ATS) will host a special symposium, "Alpha-1 Antitrypsin Deficiency: The Next 50 Years" on Wednesday, May 22nd as part of the ATS International Conference in Philadelphia. The invited speakers include Professor Gerry McElvaney who presents data from a study in Beaumont Hospital which clarifies the risk of COPD among MZ carriers.

How Do I Get Tested?

Free Alpha-1 Screening

For information on how to get tested for Alpha-1 please contact:

Kitty O’Connor Clinical Research Nurse, Alpha One Foundation, RCSI Education & Research Centre, Beaumont Hospital, Dublin 9.

Phone: 01-8093871

E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Alpha One Foundation can provide genetic counselling in relation to testing for Alpha-1.

The most important thing to remember is that cigarette smoke is the single biggest risk factor for lung disease in Alpha-1 individuals.

What is Alpha-1 Antitrypsin?

Alpha-1 antitrypsin is an important protein produced by the liver, which is released into the bloodstream and travels to the lungs. Once inside the lungs it provides protection from the destructive effects of infections and harmful irritants, particularly tobacco smoke.

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, along with cystic fibrosis, is the commonest genetic lung disease in Ireland. It severely affects more than 2,000 people nationally, with another 10,000 individuals also at risk of lung and liver disease. It is the only proven genetic risk factor for COPD.